文献速递前列腺癌

前列腺床影像引导剂量递增挽救性放疗(SPIDER):一项国际多中心回顾性研究

Prostatectomy Bed Image-guided Dose-escalated Salvage Radiotherapy (SPIDER): An International Multicenter Retrospective Study.
PubMed 文献 · Eur Urol Oncol · 2023-04-13

这项国际多中心回顾性研究纳入16个欧洲中心310例前列腺切除术后前列腺床宏观局部复发患者,评估功能影像引导挽救性放疗的疗效与安全性。中位随访54个月,5年无进展生存率和无转移生存率分别为70%和84%,晚期≥2级泌尿和胃肠道毒性分别为12%和3%。对宏观局部复发灶处方剂量≥72 Gy时,5年无进展生存率从60%提高至73%(p=0.03)。

要点

  • 前列腺床宏观局部复发患者接受剂量递增挽救性放疗,5年无进展生存率为70%。
  • 对宏观局部复发灶处方剂量≥72 Gy时,5年无进展生存率73%(95%CI 65-79)vs 60%(95%CI 48-70),p=0.03。
  • 晚期≥2级泌尿毒性和胃肠道毒性分别见于43例(12%)和11例(3%)患者。

核心结论

  • 在整合功能影像数据的本当代研究中,对前列腺床宏观局部复发患者行剂量递增≥72 Gy的挽救性放疗发现潜在疗效,且毒性可接受。
  • 作者指出,探索该宏观局部复发剂量递增策略的前瞻性数据有待获取。

研究设计与样本

  • 国际多中心回顾性研究,覆盖16个欧洲中心。
  • 纳入310例接受至少一次宏观局部复发灶剂量递增的患者和25例未接受任何剂量递增的患者。
  • 入组患者先行根治性前列腺切除术(伴或不伴盆腔淋巴结清扫)治疗局限或局部晚期前列腺腺癌,术后4周PSA<0.1 ng/ml,后出现生化复发(连续两次PSA≥0.2 ng/ml),且功能影像(多参数磁共振、胆碱PET/CT或前列腺特异性膜抗原PET/CT)显示前列腺床宏观局部复发病灶。
  • 排除再分期影像(CT和/或骨扫描和/或磁共振和/或PET)显示淋巴结、骨或内脏播散的患者。
  • 剂量递增定义为对前列腺床或宏观局部复发灶处方剂量>66 Gy;毒性按不良事件通用术语标准4.03版分级。

主要发现

  • 挽救性放疗前中位PSA为0.63 ng/ml(四分位距0.27-1.7),中位随访54个月(四分位距50-56)。
  • 5年无进展生存率为70%(95%CI 64-75),5年无转移生存率为84%(95%CI 78-88)。
  • 晚期≥2级泌尿毒性和胃肠道毒性分别见于43例(12%)和11例(3%)患者。
  • 对宏观局部复发灶处方剂量≥72 Gy时,接受至少一次剂量递增患者的5年无进展生存率为73%(95%CI 65-79)vs 60%(95%CI 48-70),p=0.03。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Management of macroscopic local recurrence (MLR) after radical prostatectomy is a challenging situation with no standardized approach. OBJECTIVE: The objective of our study was to assess the efficacy and safety of functional image-guided salvage radiotherapy (SRT) in patients with MLR in the prostate bed. DESIGN, SETTING, AND PARTICIPANTS: In this international multicenter retrospective study across 16 European centers, eligible patients were initially treated by radical prostatectomy (RP) with or without pelvic lymph node dissection for localized or locally advanced adenocarcinoma of the prostate. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prostate-specific antigen (PSA) measured 4 wk after RP was <0.1 ng/ml. All patients presented a biochemical relapse after RP defined by an increase in PSA level of ≥0.2 ng/ml on two successive measures. Only patients with an MLR lesion in the prostatectomy bed visualized on functional imaging (multiparametric magnetic resonance imaging, positron emission tomography/computed tomography [PET/CT] choline, or PET/CT prostate-specific membrane antigen) were eligible. Patients with lymph node, bone, or visceral dissemination at restaging imaging (CT and/or bone scintigraphy and/or magnetic resonance imaging and/or PET) were excluded. Dose escalation was defined as a dose of >66 Gy prescribed to the prostate bed or to MLR. Toxicities were classified using the Common Terminology Criteria for Adverse Events scale, version 4.03. The primary endpoint was progression-free survival (PFS). Secondary outcomes were metastasis-free survival (MPFS), biochemical progression-free survival, and overall survival. Genitourinary (GU) and gastrointestinal (GI) toxicities were analyzed. RESULTS AND LIMITATIONS: Between January 2000 and December 2019, 310 patients received at least one dose escalation on MLR and 25 patients did not receive any dose escalation. The median PSA level before SRT was 0.63 ng/ml (interquartile range [IQR], 0.27-1.7). The median follow-up was 54 mo (IQR, 50-56). Five-year PFS and MPFS were 70% (95% confidence interval [CI]: [64; 75]) and 84% (95% CI: [78; 88]), respectively. Grade ≥2 GU and GI late toxicities were observed in 43 (12%) and 11 (3%) patients, respectively. When the prescribed dose on the MLR lesion was ≥72 Gy, an improvement in 5-yr PFS was found for patients received at least one dose escalation (73% [95% CI: 65-79]) vs 60% [95% CI: 48; 70]; p = 0.03). CONCLUSIONS: In this contemporary study integrating functional imaging data, we found potential efficacy of SRT with dose escalation ≥72 Gy for patients with MLR in the prostate bed and with an acceptable toxicity profile. Prospective data exploring this MLR dose escalation strategy are awaited. PATIENT SUMMARY: In this report, we looked at the outcomes from salvage radiotherapy for prostate cancer and macroscopic relapse in a large European population. We found that outcomes varied with prostate-specific antigen at relapse, Gleason score, and dose escalation. We found potential efficacy of salvage radiotherapy with dose escalation for macroscopic relapse in the prostate bed, with an acceptable toxicity profile.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Benziane-Ouaritini N, Zilli T, Giraud A, et al. Prostatectomy Bed Image-guided Dose-escalated Salvage Radiotherapy (SPIDER): An International Multicenter Retrospective Study. Eur Urol Oncol. 2023. PMID: 37059627. doi:10.1016/j.euo.2023.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。